Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy - PubMed

Review

Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy

L Corey et al. J Antimicrob Chemother. 1983 Sep.

Abstract

Three double-blind, placebo-controlled evaluations of acyclovir were performed in first-episode genital herpes infections. In one trial intravenous acyclovir or saline was administered in hospital over 5 days. In the other two trials, 10-day courses of oral, or 7-day courses of topical acyclovir and respective placebos were followed up in the outpatient department. Regular assessments included staging examinations, culture of lesions and blood and serum analyses. No patient discontinued medication because of an adverse reaction, although one quarter of topically treated patients complained of local irritation on application. The placebo-controlled evaluations indicate that, if given within the first 7 days after the onset of lesions, topical, intravenous and oral acyclovir are useful in shortening the course of first-episode primary genital herpes. The clinical and virological effects of intravenous and oral acyclovir were more marked than those of topical treatment in the reduction of viral shedding; the time to complete healing of lesions; and in the reduction of new lesion formation. Systemic preparations of acyclovir also decreased the symptoms of herpes simplex virus urethritis and intravenous acyclovir those of herpes simplex virus cervicitis. Neither systemic treatment, however, was effective in delaying or reducing the frequency of subsequent recurrences, which may be related to the development of early ganglionic infection. Despite this, acyclovir treatment is a significant advance in the management of primary genital herpes.

Similar articles

• Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection.

  Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, Connor J, Redfield DC, Savoia MC, Richman DD, Tyrrell DL, et al. Mertz GJ, et al. JAMA. 1984 Sep 7;252(9):1147-51. JAMA. 1984. PMID: 6088819 Clinical Trial.

• Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial.

  Peacock JE Jr, Kaplowitz LG, Sparling PF, Durack DT, Gnann JW Jr, Whitley RJ, Lovett M, Bryson YJ, Klein RJ, Friedman-Kien AE, et al. Peacock JE Jr, et al. Am J Med. 1988 Sep;85(3):301-6. doi: 10.1016/0002-9343(88)90578-5. Am J Med. 1988. PMID: 3046350 Clinical Trial.

• Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy.

  Fiddian AP, Kinghorn GR, Goldmeier D, Rees E, Rodin P, Thin RN, de Konig GA. Fiddian AP, et al. J Antimicrob Chemother. 1983 Sep;12 Suppl B:67-77. doi: 10.1093/jac/12.suppl_b.67. J Antimicrob Chemother. 1983. PMID: 6355053 Review.

• Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus.

  Bryson YJ. Bryson YJ. J Antimicrob Chemother. 1983 Sep;12 Suppl B:61-5. doi: 10.1093/jac/12.suppl_b.61. J Antimicrob Chemother. 1983. PMID: 6355052 Review.

• Interventions for men and women with their first episode of genital herpes.

  Heslop R, Roberts H, Flower D, Jordan V. Heslop R, et al. Cochrane Database Syst Rev. 2016 Aug 30;2016(8):CD010684. doi: 10.1002/14651858.CD010684.pub2. Cochrane Database Syst Rev. 2016. PMID: 27575957 Free PMC article. Review.

Cited by

• Antiviral therapy: current concepts and practices.

  Bean B. Bean B. Clin Microbiol Rev. 1992 Apr;5(2):146-82. doi: 10.1128/CMR.5.2.146. Clin Microbiol Rev. 1992. PMID: 1576586 Free PMC article. Review.

• Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

  Lingappa JR, Celum C. Lingappa JR, et al. Drugs. 2007;67(2):155-74. doi: 10.2165/00003495-200767020-00001. Drugs. 2007. PMID: 17284082 Review.

• Acyclovir prophylaxis for herpes simplex virus infection.

  Gold D, Corey L. Gold D, et al. Antimicrob Agents Chemother. 1987 Mar;31(3):361-7. doi: 10.1128/AAC.31.3.361. Antimicrob Agents Chemother. 1987. PMID: 3555331 Free PMC article. Review.

• Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2.

  White PJ, Garnett GP. White PJ, et al. Sex Transm Infect. 1999 Feb;75(1):49-54. doi: 10.1136/sti.75.1.49. Sex Transm Infect. 1999. PMID: 10448343 Free PMC article.

• Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.

  Schiffer JT, Magaret A, Selke S, Corey L, Wald A. Schiffer JT, et al. J Antimicrob Chemother. 2011 Nov;66(11):2593-600. doi: 10.1093/jac/dkr346. Epub 2011 Aug 24. J Antimicrob Chemother. 2011. PMID: 21865349 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information